EA201401074A1 - Фармацевтические составы, содержащие хондроитинсульфат и производные гиалуроновой кислоты - Google Patents

Фармацевтические составы, содержащие хондроитинсульфат и производные гиалуроновой кислоты

Info

Publication number
EA201401074A1
EA201401074A1 EA201401074A EA201401074A EA201401074A1 EA 201401074 A1 EA201401074 A1 EA 201401074A1 EA 201401074 A EA201401074 A EA 201401074A EA 201401074 A EA201401074 A EA 201401074A EA 201401074 A1 EA201401074 A1 EA 201401074A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hyaluronic acid
pharmaceutical compositions
compositions containing
chondroitinsulphate
acid derivatives
Prior art date
Application number
EA201401074A
Other languages
English (en)
Other versions
EA029237B1 (ru
Inventor
Анна Мария Занеллато
Винченца Корса
Джанкарло Карпанезе
Моника Кампизи
Original Assignee
Фидиа Фармачеутичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фидиа Фармачеутичи С.П.А. filed Critical Фидиа Фармачеутичи С.П.А.
Publication of EA201401074A1 publication Critical patent/EA201401074A1/ru
Publication of EA029237B1 publication Critical patent/EA029237B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к фармацевтическим составам, содержащим комбинацию заданных производных гиалуроновой кислоты с высокой молекулярной массой и хондроитинсульфата и использующимся для лечения остеоартрита, субхондральных поражений, остеопороза, синовита, теносиновита, тендинита, тендиноза, а также в качестве внутрисуставной промывочной жидкости и вязкого заменителя синовиальной жидкости после хирургического лечения остеохондральных поражений. Данные составы также применимы для лечения интерстициального цистита.
EA201401074A 2012-03-30 2013-03-27 Вязкие смазки, содержащие хондроитин сульфат и производные гиалуроновой кислоты EA029237B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000098A ITPD20120098A1 (it) 2012-03-30 2012-03-30 "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
PCT/IB2013/052443 WO2013144867A1 (en) 2012-03-30 2013-03-27 Pharmaceutical formulations comprising chondroitin sulfate and hyaluronic acid derivatives

Publications (2)

Publication Number Publication Date
EA201401074A1 true EA201401074A1 (ru) 2015-01-30
EA029237B1 EA029237B1 (ru) 2018-02-28

Family

ID=46000143

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792023A EA201792023A3 (ru) 2012-03-30 2013-03-27 Фармацевтические составы, содержащие хондроитин сульфат и производные гиалуроновой кислоты
EA201401074A EA029237B1 (ru) 2012-03-30 2013-03-27 Вязкие смазки, содержащие хондроитин сульфат и производные гиалуроновой кислоты

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201792023A EA201792023A3 (ru) 2012-03-30 2013-03-27 Фармацевтические составы, содержащие хондроитин сульфат и производные гиалуроновой кислоты

Country Status (12)

Country Link
US (2) US9655918B2 (ru)
EP (3) EP3449927B1 (ru)
CN (1) CN104220078A (ru)
CA (1) CA2868078C (ru)
EA (2) EA201792023A3 (ru)
ES (2) ES2709799T3 (ru)
HR (1) HRP20190131T1 (ru)
IT (1) ITPD20120098A1 (ru)
PL (1) PL2946782T3 (ru)
SI (1) SI2946782T1 (ru)
TR (1) TR201901472T4 (ru)
WO (1) WO2013144867A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITPD20120098A1 (it) * 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"
ITMI20132116A1 (it) * 2013-12-18 2015-06-19 Apharm Srl Associazione di glicosamminoglicani e ciclodestrine
CN104940221A (zh) * 2015-05-13 2015-09-30 北京大清生物技术有限公司 一种用于膀胱和尿道上皮损伤修复的组合物
EP3111941A1 (en) 2015-06-30 2017-01-04 Süleyman Patir Compositions comprising chondroitin sulfate for prophylaxis or treatment of damaged articular cartilage
ES2769059T3 (es) * 2017-05-12 2020-06-24 Farco Gmbh Composición de instilación de la vejiga que contiene sulfato de condonitina (20 mg/ml), ácido hialurónico (16 mg/ml) y buffer de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para el tratamiento de la cistitis
EP3400951B1 (de) * 2017-05-12 2019-12-11 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (4,5 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
WO2019060696A1 (en) 2017-09-25 2019-03-28 Surface Pharmaceuticals, Inc. OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
CN113366025A (zh) * 2019-01-30 2021-09-07 鲍希与洛姆伯股份有限公司 交联的聚合物网络及其用途
IT201900024208A1 (it) * 2019-12-17 2021-06-17 Altergon Sa Miscele iniettabili di acido ialuronico per uso in dermoestetica
TR201922945A2 (tr) * 2019-12-31 2021-07-26 Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi Osteoartri̇t tedavi̇si̇ i̇çi̇n propoli̇s i̇çeri̇kli̇ yeni̇ bi̇r vi̇skoelasti̇k formülasyonu ve bunun üreti̇m yöntemi̇
CN111333879B (zh) * 2020-04-16 2022-08-16 山东众山生物科技有限公司 一种交联透明质酸的硫酸软骨素类化合物及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212892B (it) 1983-10-11 1989-11-30 Della Valle Francesco Acido ialuronico ottenuto per mezzodi filtrazione molecolare sprovvisto di attivita' infiammatoria e sua utilizzazione terapeutica
DK171029B1 (da) 1983-10-11 1996-04-22 Fidia Spa Hyaluronsyrefraktion, fremgangsmåde til fremstilling deraf samt ophthalmiske præparater indeholdende hyaluronsyrefraktion
US4713448A (en) 1985-03-12 1987-12-15 Biomatrix, Inc. Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues
US6051560A (en) 1986-06-26 2000-04-18 Nestle S.A. Chrondroitin sulfate/sodium hyaluronate composition
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
IT1291291B1 (it) * 1997-04-30 1999-01-07 Chemedica Sa Uso di acido ialuronico e relativi sali per la preparazione di una soluzione acquosa utile come liquido di lavaggio intra-articolare
US6872819B1 (en) * 1998-05-27 2005-03-29 Fidia Advanced Biopolymers S.R.L. Biomaterials containing hyaluronic acid derivatives in the form of three-dimensional structures free from cellular components or products thereof for the in vivo regeneration of tissue cells
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
GB0130603D0 (en) * 2001-12-20 2002-02-06 Renaissance Healthcare Europ L Improvements in or relating to ophthalmic solutions
WO2004034980A2 (en) * 2002-10-16 2004-04-29 Marcum Frank D Treatment for traumatic synovitis and damaged articular cartilage
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
ITPD20050056A1 (it) * 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
CN100594029C (zh) * 2006-07-24 2010-03-17 凌沛学 一种关节腔内注射用药物组合物
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
IT1393945B1 (it) * 2009-04-21 2012-05-17 Fidia Farmaceutici Composizioni comprendenti acido ialuronico, acido ialuronico solfatato, calcio e vitamina d3 nel trattamento delle malattie osteoarticolari e muscoloscheletriche
IT1395392B1 (it) 2009-08-27 2012-09-14 Fidia Farmaceutici Geli viscoelastici come nuovi filler
FR2954165B1 (fr) * 2009-12-18 2012-01-13 Jean-Noel Thorel Compositions injectables a usage intra-articulaire associant un agent de viscosupplementation et un milieu de croissance des fibroblastes
ITPD20120098A1 (it) * 2012-03-30 2013-10-01 Fidia Farmaceutici "nuove formulazioni faramaceutiche contenenti condroitin solfato e derivati dell'acido ialuronico"

Also Published As

Publication number Publication date
ITPD20120098A1 (it) 2013-10-01
SI2946782T1 (sl) 2019-03-29
US20170216344A1 (en) 2017-08-03
US10821131B2 (en) 2020-11-03
EA029237B1 (ru) 2018-02-28
EA201792023A3 (ru) 2018-04-30
EP2946782A2 (en) 2015-11-25
ES2887581T3 (es) 2021-12-23
PL2946782T3 (pl) 2019-04-30
EP2946782B1 (en) 2018-11-07
WO2013144867A1 (en) 2013-10-03
CA2868078A1 (en) 2013-10-03
EP2830636A1 (en) 2015-02-04
EP2946782A3 (en) 2016-02-24
CA2868078C (en) 2020-04-14
EP3449927B1 (en) 2021-06-23
ES2709799T3 (es) 2019-04-17
EA201792023A2 (ru) 2018-01-31
EP3449927A1 (en) 2019-03-06
TR201901472T4 (tr) 2019-02-21
US20150072954A1 (en) 2015-03-12
HRP20190131T1 (hr) 2019-03-22
US9655918B2 (en) 2017-05-23
CN104220078A (zh) 2014-12-17

Similar Documents

Publication Publication Date Title
EA201401074A1 (ru) Фармацевтические составы, содержащие хондроитинсульфат и производные гиалуроновой кислоты
ECSP17039547A (es) Nuevas normalizaciones y dispositivos médicos para la preparación de plasma rico en plaquetas (prp) o concentrado de médula ósea (bmc) solos o combinados con ácido hialurónico
BR112012017488A2 (pt) "dispositivo"
BR112014032990A2 (pt) seringa
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
NI201400150A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
BR112013005764A2 (pt) malha cirúrgica
BR112013032619A2 (pt) métodos e composições relacionados com reciclagem dos resíduos de polímero
CZ308492B6 (cs) Kosmetická kompozice na bázi kyseliny hyaluronové, způsob její přípravy a použití
MX2016002794A (es) Compuestos antiproliferativos.
CL2012003287A1 (es) Complejo obtenido a partir de la mezcla de sulfato de condroitina, o una de sus sales, y acido hialuronico, o una de sus sales, con alto peso molecular; composicion farmaceutica que lo comprende; composicion cosmetica; procedimiento para su preparacion, util en enfermedades de las articulaciones, los tendones y del tejido conjuntivo.
MX342131B (es) Eliminacion selectiva de celulas erosivas.
EA201501030A1 (ru) Новые отвердители и разлагаемые полимеры и композиты на их основе
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
BR112016018177A2 (pt) Novos éteres de celulose esterificados de alto peso molecular e homogeneidade
RU2014108821A (ru) Устойчивый к расщеплению сшитый низкомолекулярный гиалуронат
ECSP14013157A (es) Formulaciones liofilizadas de fgf-18
MX2014008373A (es) Conjugados antagonistas de integrina para suministro dirigido a celulas que expresan alfa-v-beta-3.
BR112015004979A2 (pt) processo para melhorar as propriedades reológicas de uma dispersão aquosa
EA201590708A1 (ru) Модифицированные производные гиалуроновой кислоты и их применение
MX2016010872A (es) Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
MX2012006265A (es) Formulaciones disacaridas hipersulfatadas.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ TM